Press Release

Ad-hoc: change in Management Board

12 November 2009

After today’s supervisory board meeting, which ended at 2.44 pm, Carl Zeiss Meditec AG (ISIN: DE0005313704) announces that in agreement with the Supervisory and Management Boards its board member Bernd Hirsch will resign from the Management Board effective November 30, 2009.

Jena, Germany | 12 November 2009 | Corporate News
Mr Hirsch is responsible for Finance and Controlling, Investor Relations, Legal and Taxes, as well as Business Process Excellence. He is leaving the company on his own accord to take up a new challenge outside the Carl Zeiss Group.
The Supervisory Board thanks Mr Hirsch for his dedicated and successful work in the Executive Board of Carl Zeiss Meditec.
The company will be announcing details of his successor in the near future.
In the interim his duties will be taken over temporarily by board members Dr. Michael Kaschke, Dr. Ludwin Monz and Ulrich Krauss.
In the financial year 2008/2009 the company exceeded the given forecast. Carl Zeiss Meditec will be publishing its annual financial statements on December 14, 2009.
Press contact Sebastian Frericks Director Investor Relations


The Carl Zeiss Group is a leading group of companies operating worldwide in the optical and optoelectronic industries that generates revenues totaling around EUR 2.1 billion (2008/09).

Carl Zeiss offers innovative solutions for the future-oriented markets "Medical and Research Solutions", "Industrial Solutions" and "Lifestyle Products". The company develops and distributes surgical microscopes, diagnostic systems for ophthalmology, microscopes, lithography optics, industrial measuring technology, planetarium technology, optronic products, camera and cine lenses, and binoculars and spotting scopes. The eyeglass business is bundled in the joint venture Carl Zeiss Vision International GmbH.
The Carl Zeiss Group has approximately 13,000 employees, including more than 8,000 in Germany. The Carl Zeiss business groups hold leading positions in their markets.

Carl Zeiss AG is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany.

Further information at


Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials.
The company creates innovative visualisation solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiotherapy.

In the 2008/2009 (30 September) financial year the approx. 2,100 employees generated revenue of approximately € 640 million. The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France.

Thirty-five percent of Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries. Carl Zeiss offers innovative solutions for the future-oriented markets "Medical and Research Solutions", "Industrial Solutions" and "Lifestyle Products". The head office of Carl Zeiss AG is in Oberkochen, Germany. In financial year 2008/2009 (balance sheet date: 30 September) the Group generated revenue of around € 2.1 billion. Carl Zeiss employs almost 13,000 staff, over 8,000 thereof in Germany.

For more information please go to: